Series C - BioVersys
Investment Firm
Overview
BioVersys is a privately held Swiss biopharmaceutical company.
Announced Date
May 07, 2024
Funding Type
Series C
Highlights
N/A
Location
N/A
Social
N/A
Investor Lead
N/A
Participant Investors
1
| Investor Name |
|---|
 GSK |
Round Details and Background
BioVersys raised $13539232 on 2024-05-07 in Series C
BioVersys is a privately held Swiss biopharmaceutical company.
Company Funding History
14
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Jun 08, 2022 | - | 24.7M | ||
| Jan 05, 2023 | 1 | - | 9.0M | |
| Apr 28, 2023 | 1 | - | undefined | |
| May 07, 2024 | 1 | - | 13.5M |
Recent Activity
News
May 07, 2024
venturelab.swiss - BioVersys strengthens tuberculosis drug development with expanded GSK collaboration and CHF 12.3 million Series C boost
News
May 07, 2024
BioVersys - BioVersys Announces Expansion of Strategic Collaboration with GSK and Extension of its Series C Round by CHF 12.3 Million
News
May 07, 2024
GlobeNewswire News Room - BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million
News
May 07, 2024
TradingView - BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million